-
公开(公告)号:US08623825B2
公开(公告)日:2014-01-07
申请号:US12671678
申请日:2008-07-31
申请人: Fabiana Bar-Yoseph , Dori Pelled , Yael Lifshitz
发明人: Fabiana Bar-Yoseph , Dori Pelled , Yael Lifshitz
IPC分类号: A61K38/00
CPC分类号: A61K31/231 , A21D2/165 , A23D9/00 , A23L33/115 , A23L33/40 , A23V2002/00 , A61K31/23 , A23V2200/306 , A23V2250/18
摘要: Disclosed is describes a method of increasing bone strength and/or increasing bone resistance to bending and/or improving bone architecture and/or maintaining bone status in a human, comprising administering to said human a composition comprising a fat source, wherein said fat source is a triglyceride fat source comprising triglycerides with 15-55% palmitic acid moieties out of the total fatty acids, and wherein the level of palmitic acid moieties at the sn-2 position of the glycerol backbone is at least 30% (w/w) of total palmitic acid. Said method is particularly intended for subjects at risk of impaired bone strength. Further disclosed is said fat source, as well as food articles and a commercial package comprising the same.
摘要翻译: 公开了一种增加骨强度和/或增加骨抗性以改善骨架构和/或改善人体骨骼状态的方法,包括对所述人施用包含脂肪源的组合物,其中所述脂肪来源是 甘油三酸酯脂肪源包括在总脂肪酸中具有15-55%的棕榈酸部分的甘油三酸酯,并且其中在甘油骨架的sn-2位置处的棕榈酸部分的水平为至少30%(w / w) 总棕榈酸。 所述方法特别适用于具有骨强度受损的风险的受试者。 进一步公开的是脂肪源,以及食品和包含该食品的商业包装。
-
公开(公告)号:US20110244071A1
公开(公告)日:2011-10-06
申请号:US12671678
申请日:2008-07-31
申请人: Fabiana Bar-Yoseph , Dori Pelled , Yael Lifshitz
发明人: Fabiana Bar-Yoseph , Dori Pelled , Yael Lifshitz
CPC分类号: A61K31/231 , A21D2/165 , A23D9/00 , A23L33/115 , A23L33/40 , A23V2002/00 , A61K31/23 , A23V2200/306 , A23V2250/18
摘要: Disclosed is describes a method of increasing bone strength and/or increasing bone resistance to bending and/or improving bone architecture and/or maintaining bone status in a human, comprising administering to said human a composition comprising a fat source, wherein said fat source is a triglyceride fat source comprising triglycerides with 15-55% palmitic acid moieties out of the total fatty acids, and wherein the level of palmitic acid moieties at the sn-2 position of the glycerol backbone is at least 30% (w/w) of total palmitic acid. Said method is particularly intended for subjects at risk of impaired bone strength. Further disclosed is said fat source, as well as food articles and a commercial package comprising the same.
摘要翻译: 公开了一种增加骨强度和/或增加骨抗性以改善骨架构和/或改善人体骨骼状态的方法,包括对所述人施用包含脂肪源的组合物,其中所述脂肪来源是 甘油三酸酯脂肪源包括在总脂肪酸中具有15-55%的棕榈酸部分的甘油三酸酯,并且其中在甘油骨架的sn-2位置处的棕榈酸部分的水平为至少30%(w / w) 总棕榈酸。 所述方法特别适用于具有骨强度受损的风险的受试者。 进一步公开的是脂肪源,以及食品和包含该食品的商业包装。
-
公开(公告)号:US09168310B2
公开(公告)日:2015-10-27
申请号:US14063401
申请日:2013-10-25
申请人: Gai Ben Dror , Dorit Platt , Orly Farkash , Rassan Zuabi , Zohar Bar-On , Avidor Shulman , Dori Pelled , Yael Richter
发明人: Gai Ben Dror , Dorit Platt , Orly Farkash , Rassan Zuabi , Zohar Bar-On , Avidor Shulman , Dori Pelled , Yael Richter
CPC分类号: A61K47/544 , A21D2/32 , A23D7/013 , A23D9/013 , A23L33/12 , A23L33/30 , A23L33/40 , A23V2002/00 , A61K31/201 , A61K31/202 , A61K31/66 , A61K31/685 , C07F9/10 , A23V2200/322 , A23V2250/1882 , A23V2250/1942 , A23V2250/1842
摘要: The invention described herein provides a preparation comprising a non-mammalian derived mixture of serine glycerophospholipid conjugates with a specific content and specific conjugation patterns of LA, linolenic acid (alpha-linolenic acid, gamma-linolenic acid) DHA and EPA which depend on utilizing different sources of lipids, and uses of such preparations.
摘要翻译: 本文描述的本发明提供包含非哺乳动物衍生的丝氨酸甘油磷脂缀合物的混合物的制剂,其具有LA,亚麻酸(α-亚麻酸,γ-亚麻酸)DHA和EPA的特定含量和特异性缀合图案,其依赖于使用不同的 脂质来源,以及这些制剂的用途。
-
公开(公告)号:US08470345B2
公开(公告)日:2013-06-25
申请号:US12590893
申请日:2009-11-16
申请人: Gai Ben Dror , Dorit Platt , Orly Farkash , Rassan Zuabi , Zohar Bar-On , Avidor Shulman , Dori Pelled
发明人: Gai Ben Dror , Dorit Platt , Orly Farkash , Rassan Zuabi , Zohar Bar-On , Avidor Shulman , Dori Pelled
IPC分类号: A61K31/685 , A61P25/00
CPC分类号: A61K31/685 , A21D2/32 , A23D7/013 , A23D9/013 , A23L33/12 , A23V2002/00 , A23V2200/322 , A23V2250/1882 , A23V2250/1942 , A23V2250/1842
摘要: A lipid preparation including a glycerophospholipid or salt, conjugate and derivatives thereof, particularly phosphatidylserine (PS), phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidyl-inositol (PI), phosphatidylglycerol (PG) and phosphatidic acid (PA), and poly-unsaturated fatty acid (PUFA) acyl groups, particularly long-chain poly-unsaturated fatty acid (LC-PUFA) acyl groups such as omega-3 and/or omega-6 acyl groups, wherein said PUFA is covalently bound to said glycerophospholipid. The preparation possesses an improved bioactivity, and is useful in the treatment of various cognitive and mental conditions and disorders and for maintenance of normal functions of brain-related systems and processes.
摘要翻译: 一种包含甘油磷脂或盐的缀合物及其衍生物,特别是磷脂酰丝氨酸(PS),磷脂酰胆碱(PC),磷脂酰乙醇胺(PE),磷脂酰肌醇(PI),磷脂酰甘油(PG)和磷脂酸(PA) - 不饱和脂肪酸(PUFA)酰基,特别是长链多不饱和脂肪酸(LC-PUFA)酰基如ω-3和/或ω-6酰基,其中所述PUFA与所述甘油磷脂共价结合。 该制剂具有改善的生物活性,并且可用于治疗各种认知和精神状况和障碍,并用于维持脑相关系统和过程的正常功能。
-
公开(公告)号:US20080085320A1
公开(公告)日:2008-04-10
申请号:US11872440
申请日:2007-10-15
申请人: Gai DROR , Dorit Plat , Orly Farkash , Rassan Zuabi , Zohar Bar-on , Avidor Shulman , Dori Pelled
发明人: Gai DROR , Dorit Plat , Orly Farkash , Rassan Zuabi , Zohar Bar-on , Avidor Shulman , Dori Pelled
CPC分类号: A61K31/685 , A21D2/32 , A23D7/013 , A23D9/013 , A23L33/12 , A23V2002/00 , A23V2200/322 , A23V2250/1882 , A23V2250/1942 , A23V2250/1842
摘要: A lipid preparation including a glycerophospholipid or salt, conjugate and derivatives thereof, particularly phosphatidylserine (PS), phosphatidyicholine (PC), phosphatidylethanolamine (PE), phosphatidyl-inositol (PI), phosphatidylglycerol (PG) and phosphatidic acid (PA), and poly-unsaturated fatty acid (PUFA) acyl groups, particularly long-chain poly-unsaturated fatty acid (LC-PUFA) acyl groups such as omega-3 and/or omega-6 acyl groups, wherein said PUFA is covalently bound to said glycerophospholipid. The preparation possesses an improved bioactivity, and is useful in the treatment of various cognitive and mental conditions and disorders and for maintenance of normal functions of brain-related systems and processes.
摘要翻译: 包括甘油磷脂或盐的缀合物及其衍生物,特别是磷脂酰丝氨酸(PS),磷脂酰胆碱(PC),磷脂酰乙醇胺(PE),磷脂酰肌醇(PI),磷脂酰甘油(PG)和磷脂酸(PA) - 不饱和脂肪酸(PUFA)酰基,特别是长链多不饱和脂肪酸(LC-PUFA)酰基如ω-3和/或ω-6酰基,其中所述PUFA与所述甘油磷脂共价结合。 该制剂具有改善的生物活性,并且可用于治疗各种认知和精神状况和障碍,并用于维持脑相关系统和过程的正常功能。
-
公开(公告)号:US20160015820A1
公开(公告)日:2016-01-21
申请号:US14871260
申请日:2015-09-30
申请人: Gai Ben Dror , Dorit Platt , Orly Farkash , Rassan Zuabi , Zohar Bar-On , Avidor Shulman , Dori Pelled , Yael Richter
发明人: Gai Ben Dror , Dorit Platt , Orly Farkash , Rassan Zuabi , Zohar Bar-On , Avidor Shulman , Dori Pelled , Yael Richter
CPC分类号: A61K47/544 , A21D2/32 , A23D7/013 , A23D9/013 , A23L33/12 , A23L33/30 , A23L33/40 , A23V2002/00 , A61K31/201 , A61K31/202 , A61K31/66 , A61K31/685 , C07F9/10 , A23V2200/322 , A23V2250/1882 , A23V2250/1942 , A23V2250/1842
摘要: The invention described herein provides a preparation comprising a non-mammalian derived mixture of serine glycerophospholipid conjugates with a specific content and specific conjugation patterns of LA, linolenic acid (alpha-linolenic acid, gamma-linolenic acid) DHA and EPA which depend on utilizing different sources of lipids, and uses of such preparations.
摘要翻译: 本文描述的本发明提供包含非哺乳动物衍生的丝氨酸甘油磷脂缀合物的混合物的制剂,其具有LA,亚麻酸(α-亚麻酸,γ-亚麻酸)DHA和EPA的特定含量和特异性缀合图案,其依赖于使用不同的 脂质来源,以及这些制剂的用途。
-
公开(公告)号:US08618050B2
公开(公告)日:2013-12-31
申请号:US10576239
申请日:2004-10-21
申请人: Avidor Shulman , Gai Ben Dror , Dori Pelled
发明人: Avidor Shulman , Gai Ben Dror , Dori Pelled
IPC分类号: A61K38/00
CPC分类号: A21D2/165 , A23C11/04 , A23D7/001 , A23D9/00 , A23G3/346 , A23G2200/08 , A23G2200/12 , C11C3/08
摘要: Disclosed is a dietary ingredient comprising at least one edible lipid which does not inhibit mineral absorption, enhances mineral absorption and intake, particularly a chemically or enzymatically synthesized synthetic oil, particularly glyceride-based lipid with high levels of mono- or polyunsaturated fatty acids at positions sn-1 and sn-3 of the glycerol backbone, vegetable- and plant-derived oil, such as flax and canola oils, short and medium chains lipid, preferably MCT and an oil mimicking the triglyceride composition of human mother's milk fat and its various uses.The dietary ingredient is particularly intended for use in enhancing calcium absorption and in the prevention and/or treatment of disorders associated with depletion of bone calcium and bone density, prevention and treatment of osteoporosis, for the enhancement of bone formation and bone mass maximization and for the enhancement of bone formation in infants and young children.
摘要翻译: 公开了包含至少一种不抑制矿物质吸收的可食用脂质,增强矿物质吸收和摄入的膳食成分,特别是化学或酶合成的合成油,特别是甘油酯类脂质,其具有高水平的单不饱和脂肪酸或多不饱和脂肪酸 甘油骨架的sn-1和sn-3,植物和植物来源的油,例如亚麻和低芥酸菜子油,短链和中链脂质,优选MCT和模仿人母乳脂肪的甘油三酯组合物的油及其各种 用途。 膳食成分特别用于增强钙的吸收,以及预防和/或治疗与骨钙素和骨密度消耗相关的疾病,预防和治疗骨质疏松症,用于增强骨形成和骨量最大化以及 增强婴幼儿骨骼形成。
-
公开(公告)号:US07968112B2
公开(公告)日:2011-06-28
申请号:US11872440
申请日:2007-10-15
申请人: Gai Ben Dror , Dorit Plat , Orly Farkash , Rassan Zuabi , Zohar Bar-On , Avidor Shulman , Dori Pelled
发明人: Gai Ben Dror , Dorit Plat , Orly Farkash , Rassan Zuabi , Zohar Bar-On , Avidor Shulman , Dori Pelled
CPC分类号: A61K31/685 , A21D2/32 , A23D7/013 , A23D9/013 , A23L33/12 , A23V2002/00 , A23V2200/322 , A23V2250/1882 , A23V2250/1942 , A23V2250/1842
摘要: A lipid preparation including a glycerophospholipid or salt, conjugate and derivatives thereof, particularly phosphatidylserine (PS), phosphatidyicholine (PC), phosphatidylethanolamine (PE), phosphatidyl-inositol (PI), phosphatidylglycerol (PG) and phosphatidic acid (PA), and poly-unsaturated fatty acid (PUFA) acyl groups, particularly long-chain poly-unsaturated fatty acid (LC-PUFA) acyl groups such as omega-3 and/or omega-6 acyl groups, wherein said PUFA is covalently bound to said glycerophospholipid. The preparation possesses an improved bioactivity, and is useful in the treatment of various cognitive and mental conditions and disorders and for maintenance of normal functions of brain-related systems and processes.
摘要翻译: 包括甘油磷脂或盐的缀合物及其衍生物,特别是磷脂酰丝氨酸(PS),磷脂酰胆碱(PC),磷脂酰乙醇胺(PE),磷脂酰肌醇(PI),磷脂酰甘油(PG)和磷脂酸(PA) - 不饱和脂肪酸(PUFA)酰基,特别是长链多不饱和脂肪酸(LC-PUFA)酰基如ω-3和/或ω-6酰基,其中所述PUFA与所述甘油磷脂共价结合。 该制剂具有改善的生物活性,并且可用于治疗各种认知和精神状况和障碍,并用于维持脑相关系统和过程的正常功能。
-
公开(公告)号:US20080085319A1
公开(公告)日:2008-04-10
申请号:US11872258
申请日:2007-10-15
申请人: Gai DROR , Dorit Plat , Orly Farkash , Rassan Zuabi , Zohar Bar-on , Avidor Shulman , Dori Pelled
发明人: Gai DROR , Dorit Plat , Orly Farkash , Rassan Zuabi , Zohar Bar-on , Avidor Shulman , Dori Pelled
IPC分类号: A61K31/66 , A23D7/005 , A61K35/00 , A61K35/12 , A61K35/60 , A61K36/00 , A61K36/02 , A61P43/00
CPC分类号: A61K31/685 , A21D2/32 , A23D7/013 , A23D9/013 , A23L33/12 , A23V2002/00 , A23V2200/322 , A23V2250/1882 , A23V2250/1942 , A23V2250/1842
摘要: A lipid preparation including a glycerophospholipid or salt, conjugate and derivatives thereof, particularly phosphatidylserine (PS), phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidyl-inositol (PI), phosphatidylglycerol (PG) and phosphatidic acid (PA), and poly-unsaturated fatty acid (PUFA) acyl groups, particularly long-chain poly-unsaturated fatty acid (LC-PUFA) acyl groups such as omega-3 and/or omega-6 acyl groups, wherein said PUFA is covalently bound to said glycerophospholipid. The preparation possesses an improved bioactivity, and is useful in the treatment of various cognitive and mental conditions and disorders and for maintenance of normal functions of brain-related systems and processes.
摘要翻译: 一种包含甘油磷脂或盐的缀合物及其衍生物,特别是磷脂酰丝氨酸(PS),磷脂酰胆碱(PC),磷脂酰乙醇胺(PE),磷脂酰肌醇(PI),磷脂酰甘油(PG)和磷脂酸(PA) - 不饱和脂肪酸(PUFA)酰基,特别是长链多不饱和脂肪酸(LC-PUFA)酰基如ω-3和/或ω-6酰基,其中所述PUFA与所述甘油磷脂共价结合。 该制剂具有改善的生物活性,并且可用于治疗各种认知和精神状况和障碍,并用于维持脑相关系统和过程的正常功能。
-
10.
公开(公告)号:US20060233863A1
公开(公告)日:2006-10-19
申请号:US11396257
申请日:2006-03-31
申请人: Dorit Platt , Dori Pelled , Avidor Shulman , Gai Ben-Dror
发明人: Dorit Platt , Dori Pelled , Avidor Shulman , Gai Ben-Dror
CPC分类号: A61K31/22 , A23D9/013 , A23L33/11 , A23L33/12 , A23V2002/00 , A61K31/20 , A61K31/23 , A61K31/56 , A61K31/575 , A61K45/06 , A61K2300/00 , A23V2250/182 , A23V2250/2136
摘要: Described herein are various lipid mixtures, more particularly special mixtures of fatty acids esters, which may be phytosterol esters and/or glyceride esters. Said mixtures are evaluated in the context of their ability to, upon consumption, affect the levels of circulating LDL and HDL particles, and their therapeutic effect on conditions associated with lipid metabolism, such as atherosclerosis, diabetes, metabolic disorders, etc. Compositions, dietary nutrients, food supplements and nutraceuticals comprising the herein described mixtures are also described.
-
-
-
-
-
-
-
-
-